Two new classifications for myeloid neoplasms were introduced in 2022: the International Consensus Classification (ICC) and the 5th edition WHO Classification (WHO-HAEM5). Both classifications build ...

Somatic mutations with effects similar to those seen with VEXAS syndrome are increasingly seen as possible drivers of ...

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing (NGS) is appropriate for a patient with a myeloid neoplasm (MN), and when it ...

SAN DIEGO — Researchers found JAK-STAT mutations in a predominance of a cohort of adults with fusion-free hypereosinophilia with features suggesting myeloid neoplasms, according to data presented at ...

The new classifications included several major changes and may help identify different subtypes. The fifth edition of the World Health Organization classification (2022 WHO) and the International ...

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with Hodgkin lymphoma undergoing autologous stem cell transplant. While autologous ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...

The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. The Food and Drug ...

The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates Robust and Sustained Hematologic Response in Subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome ...

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Included are 1,096 transplants ...